VISUAL ABSTRACTMewhort
high (1) . Ischemic cardiovascular injury is prevalent and the resultant damage is often irreversible with a poor prognosis despite optimal contemporary therapies (2) . Thus, the ensuing chronic structural remodeling process leads to irreversible heart failure due to myocardial fibrosis, wall thinning, and progressive left ventricular (LV) dilatation (3) . Myocardial revascularization alone is beneficial but is incapable of completely preventing progressive remodeling, loss of systolic function, and the threatening transition to clinical heart failure.
Tissue-derived extracellular matrix (ECM) provides a critical microenvironment that supports cell survival, function, and adaptive tissue repair processes.
The ECM maintains a passive structural scaffold with biomechanical effects on cells. In addition, ECM provides a reservoir of bioactive growth factors and matricellular proteins that enable bioinductive effects that influence cell phenotype and behavior (4, 5) . Dysregulation of the ECM after ischemic injury can mediate maladaptive structural remodeling and induce a loss of function (6) . Restoring ECM integrity after ischemic injury may therefore be capable of promoting adaptive healing and functional recovery.
The epicardium is a key anatomic compartment that coordinates critical regenerative processes and pathways during neonatal heart development (7) .
Recently, the regenerative capacity of the epicardium was highlighted in the adult mammalian heart (8).
The epicardium can thus be seen as an optimal location for introducing factors that may improve the myocardial regenerative process. We therefore hypothesized that ECM applied to the epicardium can serve as a source of such factors that can promote tissue regeneration.
In keeping with this proposed therapeutic role of ECM, we found that in clinically relevant animal models of human cardiac disease the epicardial implantation of acellular tissue-derived ECM scaffolds can attenuate maladaptive structural cardiac remodeling and promote functional recovery (9, 10) .
The present study was designed to uncover the mechanism(s) underlying this therapeutic outcome that was not identified in our previous work (9, 10) . sham-treated animals (42.6 AE 7.6% vs. 33.6 AE 9.0% vs.
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28.7 AE 13.2%, respectively; p ¼ 0.0017) ( Figure 1B ).
Load-independent indices of cardiac systolic per- 
Mewhort et al. However, these data suggest that the intact ECM was biocompatible and more consistent with adaptive tissue formation and recovery.
ECM SCAFFOLD DOES NOT INCREASE LV STIFFNESS.
Implanting ECM scaffolds, a form of fibrous tissue, on the surface of the heart could have detrimental effects on chamber compliance with negative consequences over time. Accordingly, we assessed and compared LV stiffness after ECM scaffold implantation. The end-diastolic pressure-volume relationship, an index of LV stiffness, was measured by pressurevolume loop analysis at 14 weeks post-MI. LV Mewhort et al.
Bioactive ECM Scaffold Promotes Remodeling and Repair that of a noninfarcted heart. These data confirm that intact ECM scaffolds do not negatively alter LV compliance and may perhaps improve myocardial biomechanics after ischemic injury. These data also Abbreviations as in Figure 1 .
suggest that reductions in LV size were not a maladaptive side effect of increasing regional myocardial stiffness.
INTACT ECM SCAFFOLD STIMULATES VASCULOGENESIS.
To explore a paracrine-mediated mechanism of the ( Figures 3B to 3E ). These observations suggest Mewhort et al.
Bioactive ECM Scaffold Promotes Remodeling and Repair Figures 5D to 5F ). These data suggest that endogenous FGF-2 eluted from the intact ECM scaffold is, in part, responsible for observed bioinductive effects on human cardiac fibroblasts. 
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Mewhort et al. Fold change relative to control in FGF-2 (A), VEGF (B), and HGF (C) concentrations measured by multiplex assays of the conditioned media of human cardiac fibroblasts grown on plastic (n ¼ 6), intact ECM scaffold (n ¼ 6), or glutaraldehyde-inactivated ECM scaffold (n ¼ 6; Student t test). FGF-2 (D), VEGF (E), and HGF (F)
concentrations measured by multiplex assays of the conditioned media of human cardiac fibroblasts grown on plastic (n ¼ 3), intact ECM scaffold (n ¼ 3), or intact ECM scaffold in the presence of 1 mmol/l of FGF-2 receptor inhibitor PD 173074 (n ¼ 3; Student t test). Abbreviations as in Figures 1, 3 , and 4.
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Bioactive ECM Scaffold Promotes Remodeling and Repair Representative images of the human umbilical vein endothelial cell angiogenesis assays performed with no scaffold (A), intact ECM scaffold (B), and guanidine-inactivated ECM scaffolds (C). Total tubule length (D), total tubule branch length (E), number of nodes (F), and number of junctions (G) measured in human umbilical vein endothelial cell angiogenesis assays performed with serum-free media (n ¼ 7), intact ECM scaffold (n ¼ 7), and guanidine-inactivated ECM scaffold (n ¼ 7; 1-way ANOVA). Abbreviations as in Figure 1 . 
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